Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00301236 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 252
- Enrollment target
NCT00301236 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 252 participants.
The verdict
NCT00301236, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 252 participants
- Enrollment target
Study Summary
The purpose of this study is to determine which dosages of dexmethylphenidate HCl extended-release capsules may represent effective treatment for ADHD in children 6-12 years of age.
Interventions
- DRUG Dexmethylphenidate HCl extended-release capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00301236
The ClinicalTrials.gov registry entry for NCT00301236 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dexmethylphenidate HCl extended-release capsules is the first listed.
NCT00301236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00301236 about?
NCT00301236 is a clinical study titled "Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder". The purpose of this study is to determine which dosages of dexmethylphenidate HCl extended-release capsules may represent effective treatment for ADHD in children 6-12 years of age.
What is the current status of trial NCT00301236?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 252 participants. The study started on 2006-02. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00301236?
The interventions under investigation include: Dexmethylphenidate HCl extended-release capsules (DRUG).
Who is sponsoring clinical trial NCT00301236?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.